Migraine Briefs

Cutaneous allodynia prevalence comparable in patients with migraine and probable migraine


 

Key clinical point: The prevalence of cutaneous allodynia (CA) was comparable among patients with probable migraine (PM) and migraine. Anxiety, depression, and headache frequency/intensity were significant factors for CA in PM.

Major finding: Participants with PM (n=289) and migraine (n=125) showed a similar prevalence of CA (14.5% vs. 16.0%; P = .701). The factors significantly associated with CA in PM were moderate (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.1-5.4) and severe (aOR, 4.0; 95% CI, 1.1-13.9) headache intensity, anxiety (aOR, 5.2; 95% CI, 1.7-16.3), and depression (aOR, 3.3; 95% CI, 1.5-7.6).

Study details: The data come from the Korean Sleep-Headache Study, a population-based, cross-sectional survey on headache and sleep involving 2,501 participants.

Disclosures: This study was supported by the National Research Foundation of Korea grant from the Korean government. S‐J Cho and M K Chu were site investigators for a multicenter trial sponsored by Otsuka Korea, Eli Lilly and Co., and others. S-J Cho and MK Chu have worked as advisory members for Teva and have declared research support/lecture honoraria/grants from different sources. The other authors declared no conflicts of interest.

Source: Han SM et al. Sci Rep. 2021 Jan 28. doi: 10.1038/s41598-021-82080-z.

Recommended Reading

Erenumab improves functional outcomes in patients with episodic migraine
Migraine ICYMI
Acute care of migraine and cluster headaches: Mainstay treatments and emerging strategies
Migraine ICYMI
Lasmiditan demonstrates superior pain freedom at 2 hours in at least 2 of 3 migraine attacks
Migraine ICYMI
Galcanezumab may alleviate severity and symptoms of migraine
Migraine ICYMI
Is the keto diet effective for refractory chronic migraine?
Migraine ICYMI
Impact of comorbid migraine on propranolol efficacy for painful TMD
Migraine ICYMI
Adherence and discontinuation limit triptan outcomes
Migraine ICYMI
Can percutaneous patent foramen closure reduce migraine?
Migraine ICYMI
Dietary magnesium may have a protective role against migraine
Migraine ICYMI
Acute migraine treatment: Real-world data reaffirm efficacy and safety of ubrogepant
Migraine ICYMI